scholarly journals P3.12-16 Prognostic Impact of M Descriptors of the 8th Edition of TNM Classification for Extensive Disease-Small Cell Lung Cancer

2018 ◽  
Vol 13 (10) ◽  
pp. S975-S976
Author(s):  
M. Shirasawa ◽  
T. Fukui ◽  
S. Kusuhara ◽  
Y. Hiyoshi ◽  
M. Ishihara ◽  
...  
2018 ◽  
Vol Volume 10 ◽  
pp. 6039-6047 ◽  
Author(s):  
Masayuki Shirasawa ◽  
Tomoya Fukui ◽  
Seiichiro Kusuhara ◽  
Yasuhiro Hiyoshi ◽  
Mikiko Ishihara ◽  
...  

2017 ◽  
Vol 12 (3) ◽  
pp. 520-528 ◽  
Author(s):  
Junghoon Shin ◽  
Bhumsuk Keam ◽  
Miso Kim ◽  
Young Sik Park ◽  
Tae Min Kim ◽  
...  

2017 ◽  
Vol 12 (1) ◽  
pp. S585-S586
Author(s):  
Matthew Smeltzer ◽  
Nicholas Faris ◽  
Carrie Fehnel ◽  
Cheryl Houston-Harris ◽  
Meredith Ray ◽  
...  

2019 ◽  
Vol 27 (2) ◽  
pp. 481-489 ◽  
Author(s):  
Shuichi Shinohara ◽  
Ryo Otsuki ◽  
Kenichi Kobayashi ◽  
Masaki Matsuo ◽  
Ken Harada ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 998
Author(s):  
Chiara Lazzari ◽  
Aurora Mirabile ◽  
Alessandra Bulotta ◽  
Maria Grazia Viganó ◽  
Francesca Rita Ogliari ◽  
...  

Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.


Sign in / Sign up

Export Citation Format

Share Document